- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00292227
Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's Disease
Double-blind, Randomized, Placebo- and Positive-controlled, Parallel-group Trial to Assess the Potential Electrocardiographic Effects of Rotigotine Transdermal System up to 120 cm2/54.0 mg/Day in Subjects With Advanced-stage Idiopathic Parkinson's Disease: A Thorough QT/QTc Trial.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Bloemfontein, South Africa
- Farmovs-Parexel (Pty) Ltd
-
George, South Africa
- Qdot, a division of Parexel International DA (Pty) Ltd.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female at least 18 years of age
- Advanced-stage idiopathic Parkinson's disease requiring treatment with levodopa.
- Nonchildbearing potential
Exclusion Criteria:
- Atypical Parkinson's syndrome(s).
- History of pallidotomy, thalamotomy, deep brain stimulation, or fetal tissue transplant.
- Significant tremor or dyskinesias.
- Severe dysfunction of the autonomic nervous system.
- History of transient ischemic attack or stroke within the last 12 months.
- Conduction abnormality or relevant cardiac dysfunction and/or myocardial infarction within last 12 months.
- History or current condition of additional risk factors for Torsade de Pointes (eg, heart failure, hypokalemia), or a family history of long QT syndrome and/or of Torsade de Pointes.
- No stable sinus rhythm: more than 20 ectopics/h.
- Any other clinically relevant ECG abnormality.
- History or current condition of epilepsy and/or seizures.
- History or current condition of atopic or eczematous dermatitis, psoriasis, or another active skin disease.
- History or current condition of symptomatic orthostatic hypotension.
- History or current condition of significant skin hypersensitivity to adhesives or other transdermal products or recent unresolved contact dermatitis.
- History of glucose 6-phosphate dehydrogenase deficiency.
- History of tendonitis or tendon rupture with quinolone antibiotics.
- Renal or hepatic dysfunction.
- Treatment with dopamine agonists, MAO A inhibitors, reserpine, or alpha-methyldopa
- Therapy known to produce a nontrivial prolongation of the QT interval.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Rotigotine
Rotigotine Patch
|
Rotigotine patch applied once daily for a 24-hour period. Rotigotine dose schedule (patch application days): Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;
Other Names:
Placebo saline solution 250 mL infused over 1h once either on Day 32 or on Day 39
Placebo saline solution 250 mL infused over 1h once on both Day 32 and on Day 39
|
Placebo Comparator: Placebo
Placebo patch
|
Placebo saline solution 250 mL infused over 1h once either on Day 32 or on Day 39
Placebo saline solution 250 mL infused over 1h once on both Day 32 and on Day 39
Placebo patch applied once daily for a 24-hour period. Size and number of patches matching to rotigotine dose schedule (patch application days): Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;
Moxifloxacin 400 mg/250 mL iv solution infused over 1h once either on Day 32 or on Day 39
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI at Time of Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 20:00h, Day 42 20:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 20:00h.
|
Baseline (Day -2/ Day -1) 20:00h, Day 42 20:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 1 Hour After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 21:00h, Day 42 21:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 21:00h.
|
Baseline (Day -2/ Day -1) 21:00h, Day 42 21:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 2 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 22:00h, Day 42 22:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 22:00h.
|
Baseline (Day -2/ Day -1) 22:00h, Day 42 22:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 3 Hours After Patch Application on Day 42(Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 23:00h, Day 42 23:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 23:00h.
|
Baseline (Day -2/ Day -1) 23:00h, Day 42 23:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 4 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 00:00h, Day 43 00:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 00:00h.
|
Baseline (Day -2/ Day -1) 00:00h, Day 43 00:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 5 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 1:00h, Day 43 1:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 1:00h.
|
Baseline (Day -2/ Day -1) 1:00h, Day 43 1:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 6 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 2:00h, Day 43 2:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 2:00h.
|
Baseline (Day -2/ Day -1) 2:00h, Day 43 2:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 7 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 3:00h, Day 43 3:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 3:00h.
|
Baseline (Day -2/ Day -1) 3:00h, Day 43 3:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 8 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 4:00h, Day 43 4:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 4:00h.
|
Baseline (Day -2/ Day -1) 4:00h, Day 43 4:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 9 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 5:00h, Day 43 5:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 5:00h.
|
Baseline (Day -2/ Day -1) 5:00h, Day 43 5:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 10 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 6:00h, Day 43 6:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 6:00h.
|
Baseline (Day -2/ Day -1) 6:00h, Day 43 6:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 11 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 7:00h, Day 43 7:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 7:00h.
|
Baseline (Day -2/ Day -1) 7:00h, Day 43 7:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 12 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 8:00h, Day 43 8:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 8:00h.
|
Baseline (Day -2/ Day -1) 8:00h, Day 43 8:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 13 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 9:00h, Day 43 9:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 9:00h.
|
Baseline (Day -2/ Day -1) 9:00h, Day 43 9:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 14 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 10:00h, Day 43 10:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 10:00h.
|
Baseline (Day -2/ Day -1) 10:00h, Day 43 10:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 15 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 11:00h, Day 43 11:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 11:00h.
|
Baseline (Day -2/ Day -1) 11:00h, Day 43 11:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 16 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 12:00h, Day 43 12:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 12:00h.
|
Baseline (Day -2/ Day -1) 12:00h, Day 43 12:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 17 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 13:00h, Day 43 13:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 13:00h.
|
Baseline (Day -2/ Day -1) 13:00h, Day 43 13:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 18 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 14:00h, Day 43 14:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 14:00h.
|
Baseline (Day -2/ Day -1) 14:00h, Day 43 14:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 19 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 15:00h, Day 43 15:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 15:00h.
|
Baseline (Day -2/ Day -1) 15:00h, Day 43 15:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 20 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 16:00h, Day 43 16:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 16:00h.
|
Baseline (Day -2/ Day -1) 16:00h, Day 43 16:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 21 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 17:00h, Day 43 17:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 17:00h.
|
Baseline (Day -2/ Day -1) 17:00h, Day 43 17:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 22 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 18:00h, Day 43 18:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 18:00h.
|
Baseline (Day -2/ Day -1) 18:00h, Day 43 18:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 23 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 19:00h, Day 43 19:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 19:00h.
|
Baseline (Day -2/ Day -1) 19:00h, Day 43 19:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTc Based on the QTcI 24 Hours After Patch Application on Day 42 (Rotigotine Dose of 54 mg/Day) (Parallel-group Comparison)
Time Frame: Baseline (Day -2/ Day -1) 20:00h, Day 43 20:00h
|
Change in QTcI was analyzed by a parallel-group comparison between rotigotine patch and placebo patch.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
The baseline QTcI value was obtained from the average of the ECG assessment on Day -2 and Day -1.
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 20:00h.
|
Baseline (Day -2/ Day -1) 20:00h, Day 43 20:00h
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI 2 Hours Before Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
Time Frame: Baseline (Day -2/ Day -1) 8:00h, Day 32/ Day 39 8:00h
|
Change in QTcI was analyzed by a cross-over comparison between moxifloxacin infusion and placebo infusion.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 8:00h.
|
Baseline (Day -2/ Day -1) 8:00h, Day 32/ Day 39 8:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI 1 Hour Before Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
Time Frame: Baseline (Day -2/ Day -1) 9:00h, Day 32/ Day 39 9:00h
|
Change in QTcI was analyzed by a cross-over comparison between moxifloxacin infusion and placebo infusion.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 9:00h.
|
Baseline (Day -2/ Day -1) 9:00h, Day 32/ Day 39 9:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI at Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
Time Frame: Baseline (Day -2/ Day -1) 10:00h, Day 32/ Day 39 10:00h
|
Change in QTcI was analyzed by a cross-over comparison between moxifloxacin infusion and placebo infusion.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 10:00h.
|
Baseline (Day -2/ Day -1) 10:00h, Day 32/ Day 39 10:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI 1 Hour After Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
Time Frame: Baseline (Day -2/ Day -1) 11:00h, Day 32/ Day 39 11:00h
|
Change in QTcI was analyzed by a cross-over comparison between moxifloxacin infusion and placebo infusion.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 11:00h.
|
Baseline (Day -2/ Day -1) 11:00h, Day 32/ Day 39 11:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI 2 Hours After Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
Time Frame: Baseline (Day -2/ Day -1) 12:00h, Day 32/ Day 39 12:00h
|
Change in QTcI was analyzed by a cross-over comparison between moxifloxacin infusion and placebo infusion.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 12:00h.
|
Baseline (Day -2/ Day -1) 12:00h, Day 32/ Day 39 12:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI 3 Hours After Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
Time Frame: Baseline (Day -2/ Day -1) 13:00h, Day 32/ Day 39 13:00h
|
Change in QTcI was analyzed by a cross-over comparison between moxifloxacin infusion and placebo infusion.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 13:00h.
|
Baseline (Day -2/ Day -1) 13:00h, Day 32/ Day 39 13:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI 4 Hours After Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
Time Frame: Baseline (Day -2/ Day -1) 14:00h, Day 32/ Day 39 14:00h
|
Change in QTcI was analyzed by a cross-over comparison between moxifloxacin infusion and placebo infusion.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 14:00h.
|
Baseline (Day -2/ Day -1) 14:00h, Day 32/ Day 39 14:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI 5 Hours After Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
Time Frame: Baseline (Day -2/ Day -1) 15:00h, Day 32/ Day 39 15:00h
|
Change in QTcI was analyzed by a cross-over comparison between moxifloxacin infusion and placebo infusion.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 15:00h.
|
Baseline (Day -2/ Day -1) 15:00h, Day 32/ Day 39 15:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI 6 Hours After Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
Time Frame: Baseline (Day -2/ Day -1) 16:00h, Day 32/ Day 39 16:00h
|
Change in QTcI was analyzed by a cross-over comparison between moxifloxacin infusion and placebo infusion.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 16:00h.
|
Baseline (Day -2/ Day -1) 16:00h, Day 32/ Day 39 16:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI 7 Hours After Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
Time Frame: Baseline (Day -2/ Day -1) 17:00h, Day 32/ Day 39 17:00h
|
Change in QTcI was analyzed by a cross-over comparison between moxifloxacin infusion and placebo infusion.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 17:00h.
|
Baseline (Day -2/ Day -1) 17:00h, Day 32/ Day 39 17:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI 8 Hours After Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
Time Frame: Baseline (Day -2/ Day -1) 18:00h, Day 32/ Day 39 18:00h
|
Change in QTcI was analyzed by a cross-over comparison between moxifloxacin infusion and placebo infusion.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 18:00h.
|
Baseline (Day -2/ Day -1) 18:00h, Day 32/ Day 39 18:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI 9 Hours After Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
Time Frame: Baseline (Day -2/ Day -1) 19:00h, Day 32/ Day 39 19:00h
|
Change in QTcI was analyzed by a cross-over comparison between moxifloxacin infusion and placebo infusion.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 19:00h.
|
Baseline (Day -2/ Day -1) 19:00h, Day 32/ Day 39 19:00h
|
Time-matched Change From Baseline (Average of Day -2 and Day -1) in QTcI 10 Hours After Start of Infusion on Day 32 or Day 39 (Positive Control) and Respective Day 39 or Day 32 (Corresponding Placebo) (Cross-over Comparison)
Time Frame: Baseline (Day -2/ Day -1) 20:00h, Day 32/ Day 39 20:00h
|
Change in QTcI was analyzed by a cross-over comparison between moxifloxacin infusion and placebo infusion.
The QT interval refers to the respective time interval in the Electrocardiogram (ECG).
The QT interval was corrected for heart rate using an individualized heart rate correction formula including QT/RR curvature optimization (QTcI).
Absolute values are presented as unadjusted Mean and Standard Deviation.
Baseline and final measures were taken at 20:00h.
|
Baseline (Day -2/ Day -1) 20:00h, Day 32/ Day 39 20:00h
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Malik M, Andreas JO, Hnatkova K, Hoeckendorff J, Cawello W, Middle M, Horstmann R, Braun M. Thorough QT/QTc study in patients with advanced Parkinson's disease: cardiac safety of rotigotine. Clin Pharmacol Ther. 2008 Nov;84(5):595-603. doi: 10.1038/clpt.2008.143. Epub 2008 Jul 23.
- Elshoff JP, Braun M, Andreas JO, Middle M, Cawello W. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther. 2012 Apr;34(4):966-78. doi: 10.1016/j.clinthera.2012.02.008. Epub 2012 Mar 7.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Parkinsonian Disorders
- Basal Ganglia Diseases
- Movement Disorders
- Synucleinopathies
- Neurodegenerative Diseases
- Parkinson Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Anti-Bacterial Agents
- Dopamine Agonists
- Dopamine Agents
- Moxifloxacin
- Rotigotine
Other Study ID Numbers
- SP0864
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson's Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Assistance Publique - Hôpitaux de ParisFrance Parkinson AssociationUnknownHealthy Controls | Parkinson's Disease With LRRK2 Mutation | Parkinson's Disease Without LRRK2 MutationFrance
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
Universidade Federal de PernambucoCompletedParkinson's Disease.Brazil
-
University Hospital, GrenobleCompletedParkinson's Disease (Disorder)France
-
Shanghai East HospitalShanghai iCELL Biotechnology Co., Ltd, Shanghai, ChinaRecruitingIdiopathic Parkinson's DiseaseChina
-
Beijing Tiantan HospitalRecruitingPD - Parkinson's DiseaseChina
-
AbbVieActive, not recruitingParkinson's Disease (PD)United States, Australia
-
AbbVieCompletedParkinson's Disease (PD)United States, Australia
-
BlueRock TherapeuticsMemorial Sloan Kettering Cancer CenterActive, not recruitingAdvanced Parkinson's DiseaseUnited States, Canada
Clinical Trials on Rotigotine
-
UCB PharmaOtsuka Pharmaceutical Co., Ltd.Completed
-
UCB PharmaCompleted
-
UCB Biopharma SRLTerminatedRestless Legs SyndromeUnited States
-
I.R.C.C.S. Fondazione Santa LuciaCompletedAlzheimer DiseaseItaly
-
UCB BIOSCIENCES GmbHCompleted
-
I.R.C.C.S. Fondazione Santa LuciaAlzheimer's Drug Discovery FoundationActive, not recruitingMental Disorders | Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Neurologic Manifestations | Neurobehavioral Manifestations | Neurocognitive Disorders | Neurodegenerative Diseases | TDP-43 Proteinopathies | Proteostasis Deficiencies | Dementia | Language Disorders | Communication... and other conditionsItaly
-
UCB BIOSCIENCES GmbHPharmaceutical Health Sciences; Bracket GlobalCompleted
-
Otsuka Pharmaceutical Co., Ltd.CompletedIdiopathic Restless Legs Syndrome
-
Otsuka Pharmaceutical Co., Ltd.Completed